Patients
cancer
ONCOLOGY, CANCER, DISEASE PROGRESSION
The study was conducted between February 22, 2019, and March 19, 2021. Thirty patients were enrolled (n = 3, MK-8353 50 mg + selumetinib 25 mg; n = 12, MK-8353 100 mg + selumetinib 50 mg; n = 15, MK-8353 150 mg + selumetinib 75 mg). Median (range) age was 61.5 (26−78) years, 16 patients (53%) were men, 21 patients (70%) had a baseline ECOG performance status of 1, and 93% had received previous cancer therapy (Table 
Patient Demographics and Baseline Characteristics (APaT Population)59.0(48−64)59.5(26−73)66.0(27−78)61.5(26−78)APaT, all patients as treated; ECOG, Eastern Cooperative Oncology GroupData are presented as n (%) unless specified otherwiseAll patients discontinued study treatment (n = 17, disease progression; n = 6, physician decision; n = 4, AE; n = 3, patient withdrawal). Median (range) time on therapy was 49 (3−246) days, and patients participated in a median (range) of 3 (1−11) treatment cycles.